Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript Summary
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript Summary
GAAP net loss widened in Q3 2024 to $12.7 million, up from $10.6 million a year earlier, whereas the non-GAAP net loss increased to $9.4 million from $8.5 million.The following is a summary of the Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript:
以下是Pulse Biosciences, Inc. (PLSE) 2024年第三季度業績會交易記錄摘要：
Financial Performance:
金融業績：
In Q3 2024, GAAP costs and expenses increased by $2.4 million to $13.7 million, primarily driven by an increase in non-cash stock-based compensation, reaching $3 million.
Non-GAAP costs and expenses were up $1.2 million, reaching $10.4 million.
GAAP net loss widened in Q3 2024 to $12.7 million, up from $10.6 million a year earlier, whereas the non-GAAP net loss increased to $9.4 million from $8.5 million.
After completing a rights offering in July, raising $60 million, cash and equivalents stood at $79 million as of September 30, 2024.
2024年第三季度，根據GAAP標準，成本和費用增加了240萬美元，達到1370萬美元，主要受非現金股票補償增加的影響，達到300萬美元。
根據非GAAP標準，成本和費用上漲120萬美元，達到1040萬美元。
2024年第三季度，按照GAAP標準，淨虧損從一年前的1060萬美元增至1270萬美元，而按照非GAAP標準，淨虧損從850萬美元增至940萬美元。
在7月完成權益發行後，籌集了6000萬美元，截至2024年9月30日，現金及其等值物爲7900萬美元。
Business Progress:
業務進展：
Pulse Biosciences achieved significant clinical advancements with their proprietary Nano-PFA technology in treating Atrial Fibrillation and other soft tissue conditions.
Received U.S. FDA breakthrough device designation for their Cardiac Surgical System and launched pivotal studies to support future commercial applications.
Expanded the pilot program under no-cost evaluation agreements in the U.S. to further refine procedural techniques using nano-PFA for benign thyroid nodules treatment.
Pulse Biosciences在使用其專有的Nano-PFA科技治療心房顫動和其他軟組織疾病方面取得了重大臨床進展。
獲得美國FDA突破性設備認定，爲其心臟外科系統啓動關鍵性研究，以支持未來的商業應用。
在美國擴大了無成本評估協議的試點項目，以進一步完善使用納米PFA治療良性甲狀腺結節的操作技術。
Opportunities:
機會：
The use of nano-PFA in treating benign thyroid nodules presents a market potential exceeding $1 billion annually, with promising early clinical experiences underlining the technology's potential to offer minimally invasive and effective treatment solutions.
Increased focus on cardiological applications, particularly through nano-PFA-enhanced catheters and surgical systems, aimed at significant improvements in patient outcomes in Atrial Fibrillation treatments.
納米PFA用於治療良性甲狀腺結節每年呈現超過10億的市場潛力，早期臨床經驗表明了該技術提供微創且有效的治療方案的潛力。
加大心臟病應用的重點，特別是通過納米PFA增強導管和手術系統，在房顫治療中旨在顯著改善患者預後。
Risks:
風險：
The nano-PFA technology's adoption and efficacy are still being evaluated in clinical settings, requiring further evidence to establish its superiority and safety over existing treatment options.
納米PFA技術的應用和療效仍在臨床環境中評估中，需要進一步的證據來確立其優越性和安全性，以勝過現有的治療選擇。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
